CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huynh, H.
Right arrow Articles by Soo, K.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huynh, H.
Right arrow Articles by Soo, K.-C.
Cell Growth & Differentiation Vol. 13, 115-122, March 2002
© 2002 American Association for Cancer Research

A Possible Role for Insulin-like Growth Factor-binding Protein-3 Autocrine/Paracrine Loops in Controlling Hepatocellular Carcinoma Cell Proliferation1

Hung Huynh2, Pierce K. H. Chow, London L. P. Ooi and Khee-Chee Soo

Laboratory of Molecular Endocrinology [H. H.] and the Department of Surgical Oncology [P. K. H. C., L. L. P. O., K-C. S.], National Cancer Centre, Singapore 169610 and Department of General Surgery, Singapore General Hospital [P. K. H. C., L. L. P. O., K-C. S.], Singapore 169608

Hepatocellular carcinoma (HCC) is a common malignancy, but treatment outcomes have generally remained poor. Specific factors important for the pathogenesis of HCC are incompletely understood. Insulin-like growth factors (IGFs) are potent autocrine and paracrine mitogens for liver cancer cell proliferation, and their bioactivity is reduced by IGF-binding protein 3 (IGFBP-3). In the present study, we report that IGFBP-3 protein levels were either undetectable (28.5%) or low (71.5%) in human HCC samples examined compared with matched non-neoplastic liver tissue by Western blotting. IGFBP-3 was localized to nontumor liver cells by immunohistochemistry with greater immunointensity than neoplastic liver cells. Levels of type I receptor (IGF-IR) were found to be low in ~39% of human HCC samples examined compared with matched nontumor tissues. IGF-II was overexpressed in 32%, whereas IGF-I expression was decreased in 100% of HCC samples. In vitro studies revealed that IGF-I and IGF-II induced HepG2 cell proliferation in a dose-dependent manner. Treatment of HepG2 cells with either human recombinant IGFBP-3 (hrIGFBP-3) or IGF-II antibody led to a significant reduction in cell proliferation. Cotreating these cells with hrIGFBP-3 significantly attenuated the mitogenic activity of IGF-I. IGF-I-induced phosphorylation of IGF-IR ß subunit, IRS-1, mitogen-activated protein kinase, Elk-1, and Akt-1 as well as phosphatidylinositol 3'-kinase activity was significantly attenuated when hepG2 cells were pretreated with hrIGFBP-3. Our data indicate that loss of autocrine/paracrine IGFBP-3 loops may lead to HCC tumor growth and suggest that modulating production of the IGFs, IGFBP-3, and IGF-IR may represent a novel approach in the treatment of HCC.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
H. Huynh, V. C. Ngo, J. Fargnoli, M. Ayers, K. C. Soo, H. N. Koong, C. H. Thng, H. S. Ong, A. Chung, P. Chow, et al.
Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma
Clin. Cancer Res., October 1, 2008; 14(19): 6146 - 6153.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
H. Huynh, P. K.H. Chow, and K.-C. Soo
AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma
Mol. Cancer Ther., September 1, 2007; 6(9): 2468 - 2476.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
H. Huynh, K. C. Soo, P. K.H. Chow, and E. Tran
Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma
Mol. Cancer Ther., January 1, 2007; 6(1): 138 - 146.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Huynh, K. C. Soo, P. K.H. Chow, L. Panasci, and E. Tran
Xenografts of Human Hepatocellular Carcinoma: A Useful Model for Testing Drugs.
Clin. Cancer Res., July 15, 2006; 12(14): 4306 - 4314.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. W. Fong, M.-S. Chua, A. B. McKie, S. H. M. Ling, V. Mason, R. Li, P. Yusoff, T. L. Lo, H. Y. Leung, S. K.S. So, et al.
Sprouty 2, an Inhibitor of Mitogen-Activated Protein Kinase Signaling, Is Down-Regulated in Hepatocellular Carcinoma
Cancer Res., February 15, 2006; 66(4): 2048 - 2058.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Takaoka, H. Harada, C. D. Andl, K. Oyama, Y. Naomoto, K. L. Dempsey, A. J. Klein-Szanto, W. S. El-Deiry, A. Grimberg, and H. Nakagawa
Epidermal Growth Factor Receptor Regulates Aberrant Expression of Insulin-Like Growth Factor-Binding Protein 3
Cancer Res., November 1, 2004; 64(21): 7711 - 7723.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
H Reynaert, K Rombouts, A Vandermonde, D Urbain, U Kumar, P Bioulac-Sage, M Pinzani, J Rosenbaum, and A Geerts
Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma
Gut, August 1, 2004; 53(8): 1180 - 1189.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
C. K. Ong, C. Y. Ng, C. Leong, C. P. Ng, K. T. Foo, P. H. Tan, and H. Huynh
Genomic Structure of Human OKL38 Gene and Its Differential Expression in Kidney Carcinogenesis
J. Biol. Chem., January 2, 2004; 279(1): 743 - 754.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
L. M. Neri, P. Borgatti, P. L. Tazzari, R. Bortul, A. Cappellini, G. Tabellini, A. Bellacosa, S. Capitani, and A. M. Martelli
The Phosphoinositide 3-Kinase/AKT1 Pathway Involvement in Drug and All-Trans-Retinoic Acid Resistance of Leukemia Cells
Mol. Cancer Res., January 1, 2003; 1(3): 234 - 246.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 2002 by the American Association of Cancer Research.